The Redcare Pharmacy stock was probably the biggest winner of the 2023 stock market and 2024 is also starting successfully for the online pharmacy retailer: The preliminary sales figures for the 4th quarter exceeded expectations – at 531 million euros, they were higher than ever before.

After a strong start to the year, the Redcare Pharmacy stock has now dropped a few percentage points. Profit-taking is expected after the enormous rally of the past quarters – the stock has more than tripled since the beginning of 2023. Investors are now mainly looking at the beginning of March. The final numbers and probably also an outlook for 2024 are expected here.

Redcare Pharmacy in growth mode With sales of 531 million euros, the final quarter of 2023 not only impressed, but once again exceeded expectations. Compared to the same period last year, sales increased by an impressive 62 percent. In the full year 2023, Redcare Pharmacy generated 1.8 billion euros in revenue, which is at the upper end of the forecast and 49 percent above the previous year.

Without the acquisition of Mediservice from Switzerland, the increase in sales would still be in the range of 24 percent. The customer growth in 2023 was also impressive: In Q4 of 2023, the pharmacy retailer had 10.8 million active customers – about 300,000 more than in the previous quarter and about 1.5 million more than at the start of 2023.

Redcare Pharmacy stock: Great potential – but also an enormous rally For Redcare Pharmacy, things are really going smoothly. Not only are the figures for the 2023 financial year impressive, but the e-prescription, which has been mandatory in Germany since the beginning of 2024, is expected to drive further growth. Investors are therefore eagerly awaiting the forecast for the current year and have the next date in mind. On March 5, the company will publish the final figures for 2023.

However, investors must not forget that the Redcare Pharmacy stock has already climbed around 140 percent in the past year and has priced in many good news. This increases the risk of disappointments, setbacks, and profit-taking. Nevertheless, there is still potential for further growth from Redcare Pharmacy in 2024 – in any case, there is potential for further growth.

Source: https://aktienscreener.com/